LRRK2 and Parkinson disease: As mentioned in the introduction, selective type II inhibitors are needed not only to expand the potential therapeutic arsenal to treat PD but also to create a toolkit that allows inhibition of LRRK2 in conformation-specific states to better understand the function of this protein in cells and in vivo.